Skip to main content


Northfield Blood Substitute Rejected by FDA

The Food and Drug Administration refused to approve the human blood substitute, Polyheme, for use in trauma patients suffering from severe blood loss.

Northfield, Polyheme Not Long for This World

An FDA decision to not convene a panel of blood experts to review Northfield Labs' Polyheme is a signal the agency already has decided to reject the blood substitute for approval.

Blood Sub or Not, Northfield's a Negative

With the odds stacked against Polyheme being approved, investors should think hard before chasing this stock.

Biotech Notebook: Progenics, Wyeth

Projecting potential market share for newly approved Relistor; monitoring exec moves at Introgen; and more.

Feuerstein's Biotech-Stock Mailbag

Vertex's cystic fibrosis compound shows promise, but be cautious in your enthusiasm. Also, an update on the quest for blood substitutes.

Breaking News

Disney Mobile Game Opens Up a New Universe

Familiar Disney characters populate an alternate reality in new interactive game.

Birth Control Stocks May Benefit From the Reversal of Roe v. Wade

The historic Supreme Court decision may force women to make different choices.

Something Strange is Happening With Home Prices

As mortgage rates hit fresh highs, there's something unusual going on with the real estate market.

Roe Decision Forces Disney, Netflix to Take a Political Stand

Disney, JP Morgan Chase, and outgoing Meta COO Sheryl Sandberg are just a few speaking out against the ruling.